Get the Stockscreener App
0.8955
9.21%
0.0755
Io Biotech Inc stock is traded at $0.8955, with a volume of 188.88K.
It is up +9.21% in the last 24 hours and down -27.78% over the past month.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
See More
Previous Close:
$0.82
Open:
$0.8314
24h Volume:
188.88K
Relative Volume:
0.41
Market Cap:
$58.37M
Revenue:
-
Net Income/Loss:
$-86.08M
P/E Ratio:
-0.3484
EPS:
-2.57
Net Cash Flow:
$-72.06M
1W Performance:
-14.71%
1M Performance:
-27.78%
6M Performance:
-35.11%
1Y Performance:
-9.94%
1-Day Range:
$0.82
$0.9799
1-Week Range:
$0.79
$1.04
52-Week Range:
$0.7327
$2.098
Io Biotech Inc Stock (IOBT) Company Profile
Name
Io Biotech Inc
Sector
Industry
Phone
(457) 070-2980
Address
OLE MAALOES VEH 3, COPENHAGEN
Compare IOBT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| IOBT | 0.8999 | 58.37M | 0 | -86.08M | -72.06M | -2.57 |
| VRTX | 467.50 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 761.42 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 564.61 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 230.62 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.64 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Io Biotech Inc Stock (IOBT) Latest News
HC Wainwright Decreases Earnings Estimates for IO Biotech - MarketBeat
Neuronetics (NASDAQ: STIM) Announces Key Financial Updates and FDA Clearance for Adolescent Treatment - Defense World
IO Biotech (NASDAQ:IOBT) Given "Buy" Rating at HC Wainwright - MarketBeat
IO Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences - The Manila Times
IO Biotech Reports Advancing Cancer Trials Despite Widening Q3 Losses; Cash Position at $80.2M | IOBT Stock News - StockTitan
IO Biotech Announces Participation in Upcoming Investor Conferences - Marketscreener.com
IO Biotech to Present at Jefferies, Piper Sandler Healthcare Conferences | IOBT Stock News - StockTitan
Asia stocks fall as China stimulus disappoints, deflation persists - Investing.com
IO Biotech, Inc. Announces Data from the NSCLC Cohort in the Phase 2 Basket Trial of IO102-IO103 - Marketscreener.com
Promising results for IO Biotech’s cancer vaccine By Investing.com - Investing.com Canada
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study - ForexTV.com
IO Biotech's Cancer Vaccine Shows 81% Disease Control Rate in Lung Cancer Trial | IOBT Stock News - StockTitan
Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation - Yahoo Finance
Legend Biotech Chooses Philadelphia for New R&D Center - BioBuzz
Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Declines By 12.7% - MarketBeat
Melanoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
IO Biotech, Inc. (NASDAQ:IOBT) Shares Sold by Novo Holdings A S - MarketBeat
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
Non-melanoma Skin Cancer is Predicted to Exhibit Remarkable - GlobeNewswire
Melanoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR
Melanoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA, Companies by DelveInsight - Barchart
38,076 Shares in Montauk Renewables, Inc. (NASDAQ:MNTK) Bought by Squarepoint Ops LLC - Defense World
Bank of America Boosts Voya Financial (NYSE:VOYA) Price Target to $88.00 - Defense World
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Update - MarketBeat
Norstella introduces a fully integrated data asset for biopharma - European Pharmaceutical Manufacturer
Immuno-Oncology Clinical Trials Market Valuation to Reach $18.1 Billion By 2032 - 대구포스트
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting - ForexTV.com
VerImmune Secures $4.5 Million to Drive Biotech Innovation - BioBuzz
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - The Manila Times
ARHT Media Inc. Announces Filing for Bankruptcy - The Manila Times
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's 39th Annual Meeting - Marketscreener.com
United States shares lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
5 Best Stem Cell Companies to Invest In (November 2024) - Securities.io
ProShare Advisors LLC Sells 113 Shares of Reinsurance Group of America, Incorporated (NYSE:RGA) - Defense World
Novo Holdings A S Sells 658,809 Shares of IO Biotech, Inc. (NASDAQ:IOBT) - MarketBeat
American Century Companies Inc. Purchases 75,475 Shares of Lifetime Brands, Inc. (NASDAQ:LCUT) - Defense World
PCI Pharma Services invests over $365 million in EU and US facilities - European Pharmaceutical Manufacturer
Sei Investments Co. Buys 24,363 Shares of IQVIA Holdings Inc. (NYSE:IQV) - Defense World
Cancer Vaccines Market Detailed In Recent Development to Grow - openPR
Up 41% YTD, This Standout Growth Stock Has More Upside Ahead - The Globe and Mail
U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
Investors in cash trouble should check out IO Biotech Inc (IOBT) - SETE News
Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
IO Biotech (NASDAQ:IOBT) Rating Reiterated by HC Wainwright - Defense World
IO Biotech (NASDAQ:IOBT) PT Raised to $6.00 - Defense World
IO Biotech Inc [IOBT] moved up 3.22: Why It’s Important - The DBT News
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Piper Sandler maintains Overweight rating on IO Biotech shares By Investing.com - Investing.com Canada
Io Biotech Inc Stock (IOBT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Io Biotech Inc Stock (IOBT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Novo Holdings A/S | 10% Owner |
Jul 25 '24 |
Sale |
1.33 |
51,522 |
68,339 |
4,377,927 |
| Novo Holdings A/S | 10% Owner |
Jul 26 '24 |
Sale |
1.31 |
23,478 |
30,787 |
4,354,449 |
| Novo Holdings A/S | 10% Owner |
May 10 '24 |
Sale |
1.22 |
658,809 |
802,495 |
4,429,449 |
| Novo Holdings A/S | 10% Owner |
Feb 09 '24 |
Sale |
1.50 |
658,809 |
988,411 |
5,088,258 |
| Burkavage Brian | Chief Accounting Officer |
Nov 22 '23 |
Buy |
1.03 |
5,000 |
5,175 |
11,500 |
| Burkavage Brian | Chief Accounting Officer |
Nov 21 '23 |
Buy |
0.99 |
5,000 |
4,950 |
6,500 |
3.39%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):